- Home
- KIO vs BBOT Comparison
KIO vs BBOT Comparison
Compare KIO & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KIO | BBOT |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.8M | 442.6M |
| IPO Year | 2011 | 2024 |
Fundamental Metrics
Financial Performance| Metric | KIO | BBOT |
|---|---|---|
| Price | $9.97 | $2.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $24.55 |
| AVG Volume (30 Days) | 240.8K | ★ 578.5K |
| Earning Date | 01-01-0001 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 99.93 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.02 | $3.23 |
| 52 Week High | $12.18 | $14.87 |
Technical Indicators
Market Signals| Indicator | KIO | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 29.16 | 14.95 |
| Support Level | N/A | N/A |
| Resistance Level | $11.22 | $9.36 |
| Average True Range (ATR) | 0.14 | 0.21 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 2.95 | 2.54 |
Price Performance
Historical ComparisonAbout KIO KKR Income Opportunities Fund
KKR Income Opportunities Fund operates as a closed-end registered management investment company. The Fund's main objective is to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in a portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.
About BBOT BridgeBio Oncology Therapeutics Inc.
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.